2025 annual financial data
NeuroSense Therapeutics 2025 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -11,085,000 USD and net income was -11,125,000 USD.
Operating cash flow was -7,671,000 USD.
Get free NeuroSense Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -11,085,000 USD
- Net income
- -11,125,000 USD
- Operating cash flow
- -7,671,000 USD